Rubius Therapeutics, Inc. (NASDAQ:RUBY) has made a 18.09% comeback from a 12-month low price of $13.1. It was seen 3% higher, changing the price to $15.47, when the closing bell rang on 01/11/2019. At recent session, the prices were hovering between $14.845 and $15.93. This company shares are 111.7% off its target price of $32.75 and the current market capitalization stands at $1.19B. The recent change has given its price a -14.61% deficit over SMA 50 and -53.14% deficit over its 52-week high. The stock witnessed -17.54% declines, -4.51% declines and 0% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RUBY’s volatility during a week at 10.12% and during a month it has been found around 12.83%.Rubius Therapeutics, Inc. (RUBY) Top Holders
Institutional investors currently hold around $993 million or 81.4% in RUBY stock. Look at its top three institutional owners. Flagship Pioneering Inc. owns $592.45 million in Rubius Therapeutics, Inc., which represents roughly 49.79% of the company’s market cap and approximately 59.66% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 6,226,764 shares of the stock are valued at $96.33 million. The third largest holder is Baillie Gifford & Co, which currently holds $60.48 million worth of this stock and that ownership represents nearly 5.08% of its market capitalization.Rubius Therapeutics, Inc. 13F Filings
At the end of September reporting period, 54 institutional holders increased their position in Rubius Therapeutics, Inc. (NASDAQ:RUBY) by some 64,182,626 shares, decreased positions by and held positions by . That puts total institutional holdings at 64,182,626 shares, according to SEC filings. The stock grabbed 54 new institutional investments totaling 64,182,626 shares while institutional investors sold out their entire positions totaling shares.Rubius Therapeutics, Inc. (NASDAQ:RUBY) Insider Trades
Multiple company employees have indulged in significant insider trading. Rubius Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Symonds Jonathan has acquired 25,000 shares of Rubius Therapeutics, Inc. (RUBY) in trading session dated Jul. 20, 2018. These shares are worth $575,000 and were traded at $23 each. The SEC filing shows that Cuss Francis M performed a purchase of 10,000 shares. The Director added these shares by way of transaction on Jul. 20, 2018. The company’s shares were assimilated at $23 per share worth to an investment of some $230,000 on account of Cuss Francis M.
Director, Pomerantz Roger, purchased 100 common shares of Rubius Therapeutics, Inc. (RUBY) in the open market. In a transaction dated Jul. 20, 2018, the shares were bought at an average price of $23, giving away a sum of $2,300. After this purchase, 100 common shares of RUBY are directly owned by the insider, with total stake valued at $1,547.
In the transaction dated Jul. 20, 2018, the great number of shares acquired came courtesy the Director; Sohn Catherine A. added a total of 2,500 shares at an average price of $23, amounting to approximately $57,500. The insider now directly owns 2,500 shares worth $38,675.Rubius Therapeutics, Inc. (RUBY) Analyst Guide
Several analysts have released their opinion on Rubius Therapeutics, Inc. (NASDAQ:RUBY), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation.